Skip to main content
Pixium Vision logo

Pixium Vision — Investor Relations & Filings

Ticker · ALPIX ISIN · FR001400JX97 LEI · 96950046OPLRLKKEOO08 PA Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2019-01-08 Investor Presentation
Country FR France
Listing PA ALPIX

About Pixium Vision

https://www.pixium-vision.com/

Pixium Vision was a bioelectronics company that developed bionic vision systems to restore partial sight for patients with retinal diseases. Its core technology, the PRIMA System, is a photovoltaic subretinal implant designed to treat vision loss from advanced atrophic dry age-related macular degeneration (dry AMD). The system uses specialized glasses to project near-infrared light onto the implant, which converts the light into electrical signals to stimulate retinal cells and create a form of prosthetic vision. The company's assets, including the PRIMA technology and its ongoing European pivotal trial (PRIMAvera), were acquired by Science Corporation in late 2023. The trials and device manufacturing are now sponsored by La Science SAS.

Recent filings

Filing Released Lang Actions
PRIMA 6 month
Investor Presentation Classification · 92% confidence The document is a press release dated January 8, 2019, announcing positive interim clinical study results for the PRIMA system in treating dry Age-related Macular Degeneration (AMD). It details clinical endpoints met, safety data, and future study plans (pivotal study preparation). This content aligns best with an Earnings Release (ER) or a general announcement of significant operational/clinical progress, which often accompanies or precedes formal financial reports. Since it is a detailed announcement of clinical/operational milestones rather than just key financial figures (ER) or a full quarterly/annual report (IR/10-K), and it is not a transcript, presentation, or formal regulatory filing notice, the closest fit among the provided options for a significant, non-financial-only operational update is often categorized under general announcements or, if it contains key performance indicators (even clinical ones), an Earnings Release (ER) if it's the primary communication vehicle for period-end updates. However, given the focus is purely on clinical trial results and future trial planning, and it is not explicitly labeled as an 'Earnings Release' but rather a 'press release' announcing study results, it functions as a major operational update. In many databases, such detailed clinical/operational updates are classified as Investor Presentations (IP) if they were slides, or sometimes as Regulatory Filings (RNS) if they don't fit elsewhere. Since it is a detailed narrative press release announcing a major milestone, and it is not a formal financial report, it is most similar in function to an Earnings Release (ER) which communicates period performance/milestones, or potentially an Investor Presentation (IP) if it were structured as slides. Given the structure and content (announcing results and future plans), ER is a strong candidate if we interpret 'Earnings' broadly to include operational performance milestones that drive future value. If we strictly adhere to financial results, it leans towards RNS as a general announcement. Given the context of a major clinical milestone announcement, which drives investor interest, I will classify it as an Investor Presentation (IP) as it functions as a detailed update for investors, even though it's in press release format, or ER. Since it's a press release announcing results, ER is often used for significant period updates. Let's re-evaluate: It is a press release announcing clinical trial success. This is a significant operational update. It is not a DEF 14A, 10-K, IR, or CT. It is not a simple notice (RPA/RNS). It is a detailed update for investors. IP (Investor Presentation) covers detailed presentations on financials, strategy, and market position. This document details strategy (PRIMA development) and results. I will select IP as the best fit for a detailed, non-financial-only operational update aimed at investors.
2019-01-08 English
liquidity contract
Regulatory Filings Classification · 95% confidence The document is a short press release dated January 3, 2019, providing an update on the company's liquidity agreement with Gilbert Dupont, detailing the shares and cash held in the liquidity account as of December 31, 2018, and comparing it to June 30, 2018. This type of announcement, which reports on specific financial arrangements or capital management activities (like maintaining liquidity reserves), does not fit neatly into the major categories like 10-K, ER, or IR. It is not a formal dividend announcement (DIV), a major shareholding change (MRQ), or a transaction in own shares (POS) in the context of a buyback program, but rather a routine update on a specific financing/liquidity mechanism. Given the options, it is most closely related to financing/capital structure updates, but since it is a routine, non-major announcement about a specific financial arrangement, and not a comprehensive report, the most appropriate general category for miscellaneous financial updates that don't fit elsewhere is 'Regulatory Filings' (RNS), or potentially 'Capital/Financing Update' (CAP). Since it details the status of a liquidity agreement, which is a form of capital management, CAP is a strong candidate. However, RNS is often used for routine, non-periodic regulatory disclosures that don't fit other specific codes. Given the nature of reporting on a specific agreement's status, I will classify it as a general Regulatory Filing (RNS) as it is a specific, non-periodic disclosure that doesn't constitute a full financing event (CAP) or a major share transaction (POS). It is a routine disclosure related to market making/liquidity provision.
2019-01-03 English
Share Capital Dec 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information on total number of voting rights and shares composing the share capital as at December 31 st, 2018" and announces the exact number of total voting rights and shares as of a specific date (December 31, 2018). This type of announcement directly relates to the company's capital structure and shareholder rights, specifically detailing the composition of voting rights. This aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a formal update on the share capital structure, or potentially 'Declaration of Voting Results & Voting Rights Announcements' (DVA), although DVA usually refers to the *results* of a vote rather than the static count of rights. Given the focus on the *number* of shares and voting rights, SHA is the most precise fit for a capital structure update. It is not an earnings release (ER), a full annual report (10-K), or a proxy statement (PSI).
2019-01-03 English
Contrat liquidite 2019
Net Asset Value Classification · 95% confidence The document is titled "Bilan annuel du contrat de liquidité Pixium Vision contracté avec la Société de Bourse Gilbert Dupont" (Annual balance sheet of the liquidity contract...). It reports the status of a liquidity contract (shares and cash balance) as of December 31, 2018, comparing it to the previous semi-annual balance (June 30, 2018). This type of regular update concerning market making or liquidity provision, especially when presented as a brief announcement, often falls under general regulatory disclosures or specific financial updates. Since it is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV), and it specifically details the status of a financial arrangement (liquidity contract), it is best classified as a general regulatory filing or announcement that doesn't fit the highly specific categories. Given the context of reporting on a specific financial arrangement's status, and lacking a better fit among the primary financial reports, 'Regulatory Filings' (RNS) is the most appropriate fallback, although it is closely related to capital structure maintenance. However, upon reviewing the definitions, none perfectly capture a 'Liquidity Contract Balance Sheet Update'. Since it is a formal, periodic update on a financial arrangement, and it is not a transaction in own shares (POS) or a capital change (CAP), RNS serves as the best general regulatory disclosure category.
2019-01-03 French
Capital social au 30 12 2018
Share Issue/Capital Change Classification · 95% confidence The document is a press release dated January 3, 2019, titled "Information relative au nombre total de droits de vote et d'actions composant le capital social au 31 décembre 2018" (Information relative to the total number of voting rights and shares comprising the share capital as of December 31, 2018). It explicitly details the total number of voting rights (real and theoretical) and the total number of shares outstanding as of a specific date. This type of mandatory periodic disclosure regarding the share capital structure and voting rights is typically classified as a notification of a change in share capital or a major shareholding notification, depending on the specific regulatory context. Given the options, the content most closely aligns with reporting changes in the capital structure, which fits the description of 'Share Issue/Capital Change' (SHA) or potentially 'Major Shareholding Notification' (MRQ) if it were focused on ownership thresholds. However, since it is a formal statement of the total capital count, it is a direct update on the capital structure. In many European contexts, this is a required disclosure related to capital changes. SHA (Share Issue/Capital Change) is the most appropriate fit among the provided codes for a formal announcement detailing the total number of shares and voting rights.
2019-01-03 French
Equity line FR
Capital/Financing Update Classification · 99% confidence The document is a press release dated December 24, 2018, announcing the establishment of a new equity financing line ('ligne de financement en fonds propres') with Kepler Cheuvreux. It details the terms, including the maximum number of shares to be issued and the mechanism for pricing (volume-weighted average price minus a discount). This activity directly relates to the company's capital structure and fundraising efforts. This fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA).
2018-12-24 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.